Castle Biosciences, Inc. (NASDAQ:CSTL – Get Free Report) insider Tobin W. Juvenal sold 3,507 shares of the company’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $35.56, for a total transaction of $124,708.92. Following the completion of the transaction, the insider now owns 54,178 shares in the company, valued at approximately $1,926,569.68. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Castle Biosciences Price Performance
CSTL traded up $0.65 on Thursday, hitting $33.31. 385,114 shares of the stock were exchanged, compared to its average volume of 324,657. Castle Biosciences, Inc. has a 12 month low of $16.20 and a 12 month high of $35.84. The business has a 50-day moving average of $30.78 and a two-hundred day moving average of $25.72. The company has a debt-to-equity ratio of 0.02, a current ratio of 8.12 and a quick ratio of 7.92. The firm has a market capitalization of $919.69 million, a price-to-earnings ratio of 168.06 and a beta of 0.99.
Castle Biosciences (NASDAQ:CSTL – Get Free Report) last posted its earnings results on Monday, November 4th. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.14. The firm had revenue of $85.78 million during the quarter, compared to analysts’ expectations of $78.55 million. Castle Biosciences had a net margin of 1.95% and a return on equity of 1.50%. During the same quarter in the prior year, the business earned ($0.26) earnings per share. Sell-side analysts forecast that Castle Biosciences, Inc. will post -0.58 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
View Our Latest Report on Castle Biosciences
Institutional Trading of Castle Biosciences
Several hedge funds have recently modified their holdings of the stock. Principal Financial Group Inc. increased its stake in shares of Castle Biosciences by 2.7% in the 3rd quarter. Principal Financial Group Inc. now owns 1,538,520 shares of the company’s stock valued at $43,879,000 after acquiring an additional 40,377 shares in the last quarter. Vanguard Group Inc. increased its stake in Castle Biosciences by 2.2% during the 1st quarter. Vanguard Group Inc. now owns 1,494,176 shares of the company’s stock valued at $33,096,000 after purchasing an additional 32,695 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Castle Biosciences by 8.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 809,934 shares of the company’s stock valued at $17,631,000 after purchasing an additional 60,675 shares in the last quarter. Renaissance Technologies LLC increased its stake in Castle Biosciences by 47.3% during the 2nd quarter. Renaissance Technologies LLC now owns 301,500 shares of the company’s stock valued at $6,564,000 after purchasing an additional 96,800 shares in the last quarter. Finally, Acadian Asset Management LLC increased its stake in Castle Biosciences by 33.0% during the 2nd quarter. Acadian Asset Management LLC now owns 280,497 shares of the company’s stock valued at $6,101,000 after purchasing an additional 69,673 shares in the last quarter. Institutional investors own 92.60% of the company’s stock.
Castle Biosciences Company Profile
Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.
Featured Stories
- Five stocks we like better than Castle Biosciences
- How Can Investors Benefit From After-Hours Trading
- Gilead’s Stock Surge: What’s Fueling the Momentum?
- What Investors Need to Know About Upcoming IPOs
- Breakout Alert: Qualcomm Just Hit The Rally Button
- Best Aerospace Stocks Investing
- Mercado Libre Shares Go on Sale: Is Now the Time to Buy?
Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.